뇌 임플란트 시장 : 시장 규모, 점유율, 성장률, 산업 분석, 유형별, 용도별, 지역별 고찰 및 예측(2026-2034년)

Growth Factors of brain implants Market

The global brain implants market is witnessing rapid growth due to the rising prevalence of neurological disorders, increasing adoption of advanced neuromodulation therapies, and strong investments in research and development by medical device manufacturers. Brain implants, also known as neural implants, are surgically implanted devices that electrically stimulate specific regions of the brain to manage neurological conditions such as epilepsy, Parkinson's disease, Alzheimer's disease, and schizophrenia.

In 2025, the global brain implants market size was valued at USD 2.36 billion. The market is projected to grow from USD 2.62 billion in 2026 to USD 6.09 billion by 2034, exhibiting a strong CAGR of 12.80% during the forecast period (2026-2034). North America dominated the global market with a 45.53% share in 2025, supported by advanced healthcare infrastructure, high diagnosis rates, and favorable reimbursement policies.

COVID-19 Impact

The COVID-19 pandemic had a negative short-term impact on the brain implants market. Temporary hospital shutdowns, postponement of elective neurosurgeries, and reduced patient visits significantly slowed market growth. According to the National Library of Medicine (November 2021), neurosurgical referrals declined by 33.6%, while operations dropped by 55.6% during the pandemic.

Key players experienced revenue declines due to supply chain disruptions and delayed procedures. For instance, Boston Scientific's neuromodulation segment recorded revenues of USD 761.0 million in 2020, reflecting a 12.8% decline from 2019. However, the market began recovering in 2021 with the resumption of surgeries and improved patient footfall.

Market Trends

Rising Focus on Flexible and Advanced Neural Probes

One of the key trends in the brain implants market is the development of flexible probes to reduce scarring caused by traditional silicon-based implants. Research institutions are exploring bendable materials such as silk fibroin and alginate to better match brain tissue softness.

In June 2023, the University of Glasgow collaborated on research exploring advanced biological materials for flexible brain probes. Additionally, the integration of cell therapy with bioelectronics is emerging as a breakthrough trend. In March 2023, the University of Cambridge developed a neural implant capable of restoring limb function in paralyzed patients.

Market Growth Drivers

Rising Prevalence of Neurological Disorders

The growing incidence of neurological disorders is a primary driver of market growth. According to WHO (January 2022), 24 million people globally suffer from schizophrenia, while Alzheimer's Association (March 2023) reported 6.7 million Americans aged 65+ living with Alzheimer's disease, projected to reach 13.8 million by 2060.

Awareness campaigns, improving diagnosis rates, and rising healthcare expenditure are further driving the adoption of brain implants globally.

Increasing R&D Investments

Medical device manufacturers are heavily investing in R&D to develop innovative and personalized brain implant technologies. In January 2023, Precision Neuroscience focused on developing the Layer 7 Cortical Interface to assist patients with paralysis, highlighting the innovation-driven growth of the market.

Restraining Factors

Despite strong growth prospects, high treatment costs and limited reimbursement in emerging economies restrict market adoption. For example, the average cost of a deep brain stimulation device ranges between USD 28,000 and USD 29,000 in Turkey, limiting accessibility in low-income regions. Additionally, poor healthcare infrastructure and limited disease awareness further restrain market penetration.

Segmentation Analysis

By Product

Deep brain stimulation dominated the market with a 65.60% share in 2026, owing to multiple FDA approvals. Vagus nerve stimulation is expected to grow significantly, while responsive neurostimulation is projected to expand at the fastest CAGR due to personalized, real-time treatment capabilities.

By Application

Epilepsy dominated the market in 2024, while Parkinson's disease accounted for 33.94% share in 2026. Alzheimer's disease is expected to grow at a higher CAGR due to rising prevalence and new product approvals.

By End-user

Hospitals led the market with a 73.35% share in 2026, driven by higher surgical volumes and improved neurological care infrastructure.

Regional Insights

• North America: Generated USD 1.07 billion in 2025; U.S. projected to reach USD 1.04 billion by 2026
• Europe: Strong growth supported by reimbursement and awareness initiatives
• Asia Pacific: Fastest CAGR due to aging population and cost-effective implants
• Rest of the World: Growth driven by improved access to neurological care

Key Industry Players

Major players include Medtronic, Boston Scientific Corporation, Abbott, NeuroPace, LivaNova PLC, and ALEVA Neurotherapeutics. Medtronic leads the market with strong product offerings and R&D investments.

Conclusion

The global brain implants market is poised for robust growth, expanding from USD 2.36 billion in 2025 to USD 6.09 billion by 2034, driven by the rising prevalence of neurological disorders, increasing adoption of neuromodulation therapies, and strong R&D investments by key players. Although high treatment costs and limited reimbursement in emerging economies pose challenges, ongoing technological advancements, growing awareness, and expanding healthcare infrastructure are expected to support sustained market expansion over the forecast period.

Segmentation By Product

• Deep Brain Stimulation
• Vagus Nerve Stimulation
• Responsive Neurostimulation

By Application

• Epilepsy
• Parkinson's Disease
• Alzheimer's Disease
• Schizophrenia
• Others

By End-user

• Hospitals
• Specialty Clinics
• Others

By Region

• North America (By Product, By Application, By End-user, By Country)
  • U.S.
  • Canada
• Europe (By Product, By Application, By End-user, By Country/Sub-Region)
  • U.K.
  • Germany
  • France
  • Spain
  • Italy
  • Scandinavia
  • Rest of Europe
• Asia Pacific (By Product, By Application, By End-user, By Country/Sub-Region)
  • Japan
  • China
  • India
  • Australia
  • Southeast Asia
  • Rest of the Asia Pacific
• Rest of the World (By Product, By Application, By End-user)

Table of Content

1. Introduction

• 1.1. Research Scope
• 1.2. Market Segmentation
• 1.3. Research Methodology
• 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

• 3.1. Market Drivers
• 3.2. Market Restraints
• 3.3. Market Opportunities
• 3.4. Market Trends

4. Key Insights

• 4.1. Prevalence of Key Neurological Disorders, By Key Countries/Regions, 2025
• 4.2. New Product Launches, By Key Players
• 4.3. Key Industry Developments - Mergers, Acquisitions, and Partnerships
• 4.4. Technological Advancements in Brain Implants
• 4.5. Regulatory Scenario, Key Regions
• 4.6. Impact of COVID-19 on the Market

5. Global Brain Implants Market Analysis, Insights and Forecast, 2021-2034

• 5.1. Market Analysis, Insights and Forecast - By Product
  • 5.1.1. Deep Brain Stimulation
  • 5.1.2. Vagus Nerve Stimulation
  • 5.1.3. Responsive Neurostimulation
• 5.2. Market Analysis, Insights and Forecast - By Application
  • 5.2.1. Epilepsy
  • 5.2.2. Parkinson's Disease
  • 5.2.3. Alzheimer's Disease
  • 5.2.4. Schizophrenia
  • 5.2.5. Others
• 5.3. Market Analysis, Insights and Forecast - By End User
  • 5.3.1. Hospitals
  • 5.3.2. Specialty Clinics
  • 5.3.3. Others
• 5.4. Market Analysis, Insights and Forecast - By Region
  • 5.4.1. North America
  • 5.4.2. Europe
  • 5.4.3. Asia Pacific
  • 5.4.4. Rest of the World

6. North America Brain Implants Market Analysis, Insights and Forecast, 2021-2034

• 6.1. Market Analysis, Insights and Forecast - By Product
  • 6.1.1. Deep Brain Stimulation
  • 6.1.2. Vagus Nerve Stimulation
  • 6.1.3. Responsive Neurostimulation
• 6.2. Market Analysis, Insights and Forecast - By Application
  • 6.2.1. Epilepsy
  • 6.2.2. Parkinson's Disease
  • 6.2.3. Alzheimer's Disease
  • 6.2.4. Schizophrenia
  • 6.2.5. Others
• 6.3. Market Analysis, Insights and Forecast - By End User
  • 6.3.1. Hospitals
  • 6.3.2. Specialty Clinics
  • 6.3.3. Others
• 6.4. Market Analysis, Insights and Forecast - By Country
  • 6.4.1. U.S.
  • 6.4.2. Canada

7. Europe Brain Implants Market Analysis, Insights and Forecast, 2021-2034

• 7.1. Market Analysis, Insights and Forecast - By Product
  • 7.1.1. Deep Brain Stimulation
  • 7.1.2. Vagus Nerve Stimulation
  • 7.1.3. Responsive Neurostimulation
• 7.2. Market Analysis, Insights and Forecast - By Application
  • 7.2.1. Epilepsy
  • 7.2.2. Parkinson's Disease
  • 7.2.3. Alzheimer's Disease
  • 7.2.4. Schizophrenia
  • 7.2.5. Others
• 7.3. Market Analysis, Insights and Forecast - By End User
  • 7.3.1. Hospitals
  • 7.3.2. Specialty Clinics
  • 7.3.3. Others
• 7.4. Market Analysis, Insights and Forecast - By Country/ Sub-region
  • 7.4.1. U.K.
  • 7.4.2. Germany
  • 7.4.3. France
  • 7.4.4. Spain
  • 7.4.5. Italy
  • 7.4.6. Scandinavia
  • 7.4.7. Rest of Europe

8. Asia Pacific Brain Implants Market Analysis, Insights and Forecast, 2021-2034

• 8.1. Market Analysis, Insights and Forecast - By Product
  • 8.1.1. Deep Brain Stimulation
  • 8.1.2. Vagus Nerve Stimulation
  • 8.1.3. Responsive Neurostimulation
• 8.2. Market Analysis, Insights and Forecast - By Application
  • 8.2.1. Epilepsy
  • 8.2.2. Parkinson's Disease
  • 8.2.3. Alzheimer's Disease
  • 8.2.4. Schizophrenia
  • 8.2.5. Others
• 8.3. Market Analysis, Insights and Forecast - By End User
  • 8.3.1. Hospitals
  • 8.3.2. Specialty Clinics
  • 8.3.3. Others
• 8.4. Market Analysis, Insights and Forecast - By Country/ Sub-region
  • 8.4.1. Japan
  • 8.4.2. China
  • 8.4.3. India
  • 8.4.4. Australia
  • 8.4.5. Southeast Asia
  • 8.4.6. Rest of the Asia Pacific

9. Rest of the World Brain Implants Market Analysis, Insights and Forecast, 2021-2034

• 9.1. Market Analysis, Insights and Forecast - By Product
  • 9.1.1. Deep Brain Stimulation
  • 9.1.2. Vagus Nerve Stimulation
  • 9.1.3. Responsive Neurostimulation
• 9.2. Market Analysis, Insights and Forecast - By Application
  • 9.2.1. Epilepsy
  • 9.2.2. Parkinson's Disease
  • 9.2.3. Alzheimer's Disease
  • 9.2.4. Schizophrenia
  • 9.2.5. Others
• 9.3. Market Analysis, Insights and Forecast - By End User
  • 9.3.1. Hospitals
  • 9.3.2. Specialty Clinics
  • 9.3.3. Others

10. Competitive Analysis

• 10.1. Global Market Share Analysis (2025)
• 10.2. Company Profiles
  • 10.2.1. Boston Scientific Corporation (U.S.)
    • 10.2.1.1. Overview
    • 10.2.1.2. SWOT Analysis
    • 10.2.1.3. Recent Developments
    • 10.2.1.4. Strategies
    • 10.2.1.5. financials (Based on Availability)
  • 10.2.2. Medtronic (Ireland)
    • 10.2.2.1. Overview
    • 10.2.2.2. SWOT Analysis
    • 10.2.2.3. Recent Developments
    • 10.2.2.4. Strategies
    • 10.2.2.5. financials (Based on Availability)
  • 10.2.3. Abbott (U.S.)
    • 10.2.3.1. Overview
    • 10.2.3.2. SWOT Analysis
    • 10.2.3.3. Recent Developments
    • 10.2.3.4. Strategies
    • 10.2.3.5. financials (Based on Availability)
  • 10.2.4. NeuroPace, Inc. (U.S.)
    • 10.2.4.1. Overview
    • 10.2.4.2. SWOT Analysis
    • 10.2.4.3. Recent Developments
    • 10.2.4.4. Strategies
    • 10.2.4.5. financials (Based on Availability)
  • 10.2.5. NDI Medical, LLC (U.S.)
    • 10.2.5.1. Overview
    • 10.2.5.2. SWOT Analysis
    • 10.2.5.3. Recent Developments
    • 10.2.5.4. Strategies
    • 10.2.5.5. financials (Based on Availability)
  • 10.2.6. ALEVA NEUROTHERAPEUTICS (Switzerland)
    • 10.2.6.1. Overview
    • 10.2.6.2. SWOT Analysis
    • 10.2.6.3. Recent Developments
    • 10.2.6.4. Strategies
    • 10.2.6.5. financials (Based on Availability)
  • 10.2.7. LivaNova PLC. (U.K.)
    • 10.2.7.1. Overview
    • 10.2.7.2. SWOT Analysis
    • 10.2.7.3. Recent Developments
    • 10.2.7.4. Strategies
    • 10.2.7.5. financials (Based on Availability)